Century Therapeutics Inc.

AI Score

XX

Unlock

0.53
-0.01 (-1.85%)
At close: Apr 24, 2025, 3:59 PM
0.53
-1.00%
Pre-market: Apr 25, 2025, 07:01 AM EDT

Century Therapeutics Statistics

Share Statistics

Century Therapeutics has 86.05M shares outstanding. The number of shares has increased by 1.83% in one year.

Shares Outstanding 86.05M
Shares Change (YoY) 1.83%
Shares Change (QoQ) 1.19%
Owned by Institutions (%) 42.97%
Shares Floating 38.84M
Failed to Deliver (FTD) Shares 5.77K
FTD / Avg. Volume 1.09%

Short Selling Information

The latest short interest is 3.13M, so 3.64% of the outstanding shares have been sold short.

Short Interest 3.13M
Short % of Shares Out 3.64%
Short % of Float 4.44%
Short Ratio (days to cover) 5.84

Valuation Ratios

The PE ratio is -0.63 and the forward PE ratio is -0.42. Century Therapeutics's PEG ratio is 0.02.

PE Ratio -0.63
Forward PE -0.42
PS Ratio 12.06
Forward PS 2.1
PB Ratio 0.49
P/FCF Ratio -0.72
PEG Ratio 0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Century Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.5, with a Debt / Equity ratio of 0.3.

Current Ratio 1.5
Quick Ratio 1.5
Debt / Equity 0.3
Debt / EBITDA -0.44
Debt / FCF -0.44
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $47.06K
Profits Per Employee $-904.04K
Employee Count 140
Asset Turnover 0.02
Inventory Turnover n/a

Taxes

Income Tax 1.79M
Effective Tax Rate -1.43%

Stock Price Statistics

The stock price has increased by -83.17% in the last 52 weeks. The beta is 1.84, so Century Therapeutics's price volatility has been higher than the market average.

Beta 1.84
52-Week Price Change -83.17%
50-Day Moving Average 0.58
200-Day Moving Average 1.27
Relative Strength Index (RSI) 50.76
Average Volume (20 Days) 531.45K

Income Statement

In the last 12 months, Century Therapeutics had revenue of 6.59M and earned -126.57M in profits. Earnings per share was -1.61.

Revenue 6.59M
Gross Profit 6.59M
Operating Income -138.14M
Net Income -126.57M
EBITDA -111.47M
EBIT -124.78M
Earnings Per Share (EPS) -1.61
Full Income Statement

Balance Sheet

The company has 58.44M in cash and 48.96M in debt, giving a net cash position of 9.48M.

Cash & Cash Equivalents 58.44M
Total Debt 48.96M
Net Cash 9.48M
Retained Earnings -782.34M
Total Assets 353.22M
Working Capital 64.27M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -110.14M and capital expenditures 0, giving a free cash flow of -110.14M.

Operating Cash Flow -110.14M
Capital Expenditures 0
Free Cash Flow -110.14M
FCF Per Share -1.4
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -2096.48% and -1920.87%.

Gross Margin 100%
Operating Margin -2096.48%
Pretax Margin -1893.7%
Profit Margin -1920.87%
EBITDA Margin -1691.79%
EBIT Margin -2096.48%
FCF Margin -1671.5%

Dividends & Yields

IPSC does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for IPSC is $2, which is 277.4% higher than the current price. The consensus rating is "Buy".

Price Target $2
Price Target Difference 277.4%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Scores

Altman Z-Score -3.88
Piotroski F-Score 3